Clinical Trial Update: Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports glycemic control outcomes for biphasic insulin aspart 70/30 in adults with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic Insulin Aspart 70/30 (insulin aspart 70/30)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED